Takeda reports positive Phase III trial results of trelagliptin succinate to treat type 2 diabetes
Trelagliptin succinate is a once-weekly dipeptidyl peptidase-IV (DPP-4) inhibitor that controls blood glucose levels by selectively and continually inhibiting DPP-4, which helps in increasing insulin secretion depending on
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.